Paper Details

  1. Home
  2. Paper Details

The Efficacy Profile of Rotigotine During the Waking Hours in Patients With Advanced Parkinson's Disease: A Post Hoc Analysis.

Author: AsgharnejadMahnaz, BauerLars, BoroojerdiBabak, ElmerLawrence W, GriegerFrank, LeWittPeter A, PoeweWerner

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Rotigotine, a transdermal dopamine agonist, shows significant reduction in "off" time for patients with Parkinson's disease.
Paper Details　
Original Abstract of the Article :
Transdermal delivery of rotigotine maintains stable plasma concentrations for 24 hours. Three phase 3 studies of rotigotine as add-on to levodopa in advanced Parkinson's disease showed a significant reduction in "off" time from baseline to end of maintenance (EoM). However, detailed analyses over th...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791317/

データ提供：米国国立医学図書館（NLM）

Rotigotine Efficacy in Advanced Parkinson's Disease

This study delves into the fascinating world of Parkinson's disease, a neurodegenerative disorder that affects movement and coordination. The researchers focus on the efficacy of rotigotine, a dopamine agonist, in managing advanced Parkinson's disease. They analyze data from three phase 3 clinical trials to investigate the time course of rotigotine's efficacy throughout the day, particularly in the context of 'off' time, a period when symptoms worsen.

Sustained Relief from Parkinson's Symptoms

The study reveals that transdermal rotigotine, with its sustained release mechanism, consistently reduces 'off' time in patients with advanced Parkinson's disease throughout the day. The researchers highlight the importance of maintaining stable plasma concentrations of rotigotine to achieve sustained relief from Parkinson's symptoms. This finding underscores the potential of rotigotine as an effective treatment option for managing advanced Parkinson's disease.

Navigating the Desert of Parkinson's

This research provides valuable insights into the management of advanced Parkinson's disease. The study demonstrates the effectiveness of rotigotine in reducing 'off' time, offering a potential path to improved quality of life for patients. It's like finding a reliable oasis in the vast desert of Parkinson's disease, providing sustained relief from debilitating symptoms and improving the lives of those affected.

Dr.Camel's Conclusion

The study showcases the efficacy of rotigotine in managing advanced Parkinson's disease, emphasizing its potential to provide sustained relief from debilitating symptoms. The findings suggest that maintaining stable plasma concentrations of rotigotine throughout the day is key to achieving optimal treatment outcomes. It's like discovering a hidden spring of relief in the vast desert of Parkinson's, offering a glimmer of hope for a better life for those affected.

Date :
  1. Date Completed 2016-12-13
  2. Date Revised 2018-11-13
Further Info :

Pubmed ID

26882318

DOI: Digital Object Identifier

PMC4791317

Related Literature

Article Analysis
・Effects of rotigotine transdermal patch
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.